Publicaciones en las que colabora con María Elena Díaz Rodríguez (24)

2022

  1. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

2020

  1. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms

    Cancer Letters, Vol. 470, pp. 161-169

2019

  1. Central role of cell cycle regulation in the antitumoral action of ocoxin

    Nutrients, Vol. 11, Núm. 5

  2. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells

    Cancer Letters, Vol. 453, pp. 34-44

2018

  1. Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer

    International Journal of Oncology, Vol. 53, Núm. 1, pp. 113-123

2017

  1. Antitumoral effect of ocoxin in hepatocellular carcinoma

    Oncology Letters, Vol. 14, Núm. 2, pp. 1950-1958

  2. Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity

    Cancer Research, Vol. 77, Núm. 17, pp. 4639-4651

2016

  1. Antitumoral effect of Ocoxin on acute myeloid leukemia

    Oncotarget, Vol. 7, Núm. 5, pp. 6231-6242

  2. Modulation of cereblon levels by anti-myeloma agents

    Leukemia and Lymphoma, Vol. 57, Núm. 1, pp. 168-176

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2014

  1. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy

    Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516

  2. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2011

  1. A modular approach to trim cellular targets in anticancer drug discovery

    Bioorganic and Medicinal Chemistry Letters, Vol. 21, Núm. 22, pp. 6641-6645

  2. Deficient spindle assembly checkpoint in multiple myeloma

    PLoS ONE, Vol. 6, Núm. 11

2010

  1. Multisite phosphorylation of Erk5 in mitosis

    Journal of Cell Science, Vol. 123, Núm. 18, pp. 3146-3156

2008

  1. Neuregulins and cancer

    Clinical Cancer Research, Vol. 14, Núm. 11, pp. 3237-3241

2002

  1. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2

    Molecular and Cellular Biology, Vol. 22, Núm. 1, pp. 270-285

  2. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor α-converting enzyme at threonine 735: A potential role in regulated shedding

    Molecular Biology of the Cell, Vol. 13, Núm. 6, pp. 2031-2044

  3. Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases

    Biochemical Journal, Vol. 363, Núm. 2, pp. 211-221